Mitchell P J, Rosenfeld J V, Dargaville P, Loughnan P, Ditchfield M R, Frawley G, Tress B M
Department of Radiology, The Royal Melbourne Hospital, University of Melbourne, Melbourne, Australia 3050.
AJNR Am J Neuroradiol. 2001 Aug;22(7):1403-9.
Neonates with vein of Galen aneurysmal malformations (VGAMs) presenting with cardiac failure have high morbidity and mortality, and outcomes are significantly better in those presenting in later childhood. Neurologic outcomes in survivors are perceived to be uniformly poor, which may lead to the neonate being denied treatment. We assessed outcomes of modern neonatal intensive care and endovascular embolization in a consecutive series of such neonates presenting with cardiac failure.
Between 1996 and 1998, five infants (three male, two female) were diagnosed with symptomatic VGAMs in the first week of life, four of whom had intractable, high-output cardiac failure and underwent initial endovascular treatment. There were 15 endovascular procedures and one neurosurgical clipping in these five patients. Transarterial and transvenous routes were required, using multiple embolic agents. We emphasized the use of sonographically guided, percutaneous transtorcular-venous-access, moveable-core guidewire as an embolic agent; routine MR imaging; and MR angiography.
Immediate outcomes included control of cardiac failure with normal neurologic function in four (80%) patients and one (20%) death from intractable cardiac failure. On follow-up examination, three (60%) infants showed no evidence of neurologic abnormality or cardiac failure; one (20%) infant showed moderate developmental delay. Two have had no further shunting on angiography, one has minimal flow, and one is awaiting follow-up imaging.
Endovascular therapy with modern neuroanesthetic and neurointensive care can provide good outcomes even in the highest-risk neonates with VGAMs and cardiac failure. If medical management of cardiac failure fails, and there is no evidence of gross cerebral parenchymal damage on imaging, urgent endovascular treatment is feasible and can reduce the almost-100% mortality otherwise expected, without invariably severe morbidity. Use of multiple embolization strategies in multiple stages usually is necessary in these patients, and novel approaches and embolic agents may be necessary.
患有大脑大静脉动脉瘤样畸形(VGAM)且出现心力衰竭的新生儿发病率和死亡率很高,而在儿童后期发病的患儿预后明显更好。人们认为幸存者的神经功能预后普遍较差,这可能导致新生儿被拒绝治疗。我们评估了一系列连续出现心力衰竭的此类新生儿接受现代新生儿重症监护和血管内栓塞治疗的预后。
1996年至1998年期间,5名婴儿(3名男性,2名女性)在出生后第一周被诊断为有症状的VGAM,其中4名患有难治性高输出量心力衰竭并接受了初始血管内治疗。这5例患者共进行了15次血管内手术和1次神经外科夹闭术。需要经动脉和经静脉途径,使用多种栓塞剂。我们强调使用超声引导下经皮经眼眶静脉穿刺、可移动芯导丝作为栓塞剂;常规磁共振成像(MR成像);以及磁共振血管造影。
即刻预后包括4例(80%)患者心力衰竭得到控制且神经功能正常,1例(20%)死于难治性心力衰竭。随访检查时,3例(60%)婴儿未显示神经异常或心力衰竭迹象;1例(20%)婴儿有中度发育迟缓。2例血管造影显示无进一步分流,1例血流极少,1例正在等待后续影像学检查。
即使是患有VGAM和心力衰竭的最高风险新生儿,采用现代神经麻醉和神经重症监护的血管内治疗也能取得良好预后。如果心力衰竭的药物治疗失败,且影像学检查未显示明显的脑实质损伤,紧急血管内治疗是可行的,可降低原本几乎100%的死亡率,且并非一定会导致严重的发病率。在这些患者中,通常需要在多个阶段使用多种栓塞策略,可能还需要新的方法和栓塞剂。